<![CDATA[Celgene International Sàrl 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=23436>Mon, 04 May 2026 18:14:31 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Celgene Receives Positive CHMP Opinion to Expand REVLIMID® (Lenalidomide) Indication as Monotherapy for the Maintenance Treatment of Patients with Newly Diagnosed Multiple Myeloma (MM) after Autologous Stem Cell Transplantation]]>https://www.newswire.co.kr/newsRead.php?no=844491Fri, 03 Feb 2017 10:10:00 +0900<![CDATA[유럽 약물사용자문위원회(CHMP), 자가 조혈모세포이식술 후 다발성 골수종으로 새로 진단된 환자의 유지치료를 위한 단독요법으로 세엘진의 ‘레블리미드’(레날리도마이드)의 적응증을 확대하도록 긍정적 의견 채택]]>https://www.newswire.co.kr/newsRead.php?no=844492Fri, 03 Feb 2017 10:10:00 +0900<![CDATA[Oral Ozanimod Efficacy and Safety Results at 2 Years from Phase 2 RADIANCE Trial of Patients with Relapsing Multiple Sclerosis Presented at 32nd ECTRIMS]]>https://www.newswire.co.kr/newsRead.php?no=835410Mon, 19 Sep 2016 10:25:00 +0900<![CDATA[Oral REVLIMID® Plus Dexamethasone Granted Approval for Treatment of Patients with Newly Diagnosed Multiple Myeloma in Japan]]>https://www.newswire.co.kr/newsRead.php?no=813319Mon, 21 Dec 2015 15:45:00 +0900<![CDATA[One Year Data from Phase III Study Evaluating Oral OTEZLA® (apremilast) or Injectable etanercept versus Placebo in Patients with Moderate to Severe Plaque Psoriasis Presented at EADV]]>https://www.newswire.co.kr/newsRead.php?no=806090Tue, 13 Oct 2015 09:50:00 +0900<![CDATA[Celgene Announces New Data for OTEZLA® (Apremilast) Will Be Presented at European Academy of Dermatology and Venereology Congress]]>https://www.newswire.co.kr/newsRead.php?no=805944Mon, 12 Oct 2015 09:25:00 +0900<![CDATA[Celgene’s VIDAZA® (Azacitidine for Injection) Receives Positive CHMP Opinion as New Treatment for Elderly Patients with Acute Myeloid Leukaemia]]>https://www.newswire.co.kr/newsRead.php?no=804705Fri, 25 Sep 2015 16:40:00 +0900<![CDATA[ABRAXANE® Approved by European Commission for First-Line Treatment of Patients with Non-Small Cell Lung Cancer]]>https://www.newswire.co.kr/newsRead.php?no=784549Tue, 03 Mar 2015 17:00:00 +0900<![CDATA[REVLIMID® (Lenalidomide) Approved by the European Commission for the Treatment of Adult Patients with Previously Untreated Multiple Myeloma who are Not Eligible for Transplant]]>https://www.newswire.co.kr/newsRead.php?no=783487Mon, 23 Feb 2015 11:55:00 +0900<![CDATA[Celgene Receives Positive CHMP Opinion for ABRAXANE® for First-Line Treatment of Patients with Non-Small Cell Lung Cancer]]>https://www.newswire.co.kr/newsRead.php?no=781262Wed, 28 Jan 2015 10:45:00 +0900<![CDATA[Oral OTEZLA® (apremilast) Approved by the European Commission for the Treatment of both Patients with Psoriasis and Psoriatic Arthritis]]>https://www.newswire.co.kr/newsRead.php?no=780396Mon, 19 Jan 2015 11:00:00 +0900<![CDATA[Celgene Receives Positive CHMP Opinion to Extend REVLIMID® (Lenalidomide) for Continuous Use in Patients with Newly Diagnosed Multiple Myeloma and Ineligible for Transplant]]>https://www.newswire.co.kr/newsRead.php?no=778132Mon, 22 Dec 2014 13:35:00 +0900<![CDATA[Phase II Data in Crohn’s Disease for Celgene’s Oral Antisense Therapy GED-0301 to Be Presented at UEG Week 2014]]>https://www.newswire.co.kr/newsRead.php?no=770606Tue, 21 Oct 2014 13:05:00 +0900<![CDATA[New Analyses of Oral OTEZLA® (Apremilast) Presented at EADV Show Efficacy in Difficult-to-Treat Areas of Moderate to Severe Plaque Psoriasis]]>https://www.newswire.co.kr/newsRead.php?no=769579Mon, 13 Oct 2014 11:40:00 +0900<![CDATA[Oral OTEZLA® (apremilast) Data Presented at EADV Show Improved Measures of Health-Related Quality of Life and Work Productivity in Patients with Moderate to Severe Plaque Psoriasis]]>https://www.newswire.co.kr/newsRead.php?no=769577Mon, 13 Oct 2014 11:35:00 +0900